multipl myeloma vmcp/vbap combin chemotherapi superior high-risk patient efficaci vincristin melphalan prednisone/vincristin carmustin doxorubicin prednison vmcp/vbap polychemotherapi prednison MP regimen induct treatment multipl myeloma MM MM patient studi march juli analysi decemb treatment group signific differ respect major prognost factor median overal surviv month vmcp/vbap MP arm induct chemotherapi cycl patient compon reduct signific differ treatment arm term remiss durat month surviv month patient year advantag polychemotherapi diagnosi plasma cell index LI serum microglobulin patient surviv patient LI equal month equal mg/l month poor-risk subgroup vmcp/vbap superior MP 